GBLP — Global Pharmatech Share Price
Last trade - 00:00- $8.26m
- $6.66m
- $2.82m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.04 | ||
| Price to Tang. Book | 1.05 | ||
| Price to Free Cashflow | 344.37 | ||
| Price to Sales | 2.6 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -25.15% | ||
| Return on Equity | -25.08% | ||
| Operating Margin | -72.63% | ||
Financial Summary
| Year End 31st Dec | Unit | 2003 | 2004 | 2005 | 2006 | 2007 | 2008E | 2009E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 3.08 | 2.13 | 2.82 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Global Pharmatech, Inc., formerly Global Pharmatech Pvt. Ltd., is a contract manufacturer of liquid sterile formulations in small volume glass vials and ampoules, and large volume glass bottles The Company has manufactured products in various therapeutic segments such as Vitamin Supplements, Anaesthetics, Corticosteroids, Anti-emetics, Steroids with antibiotics, Anemia, Analgesics, Antihistamines, Anti Filarial. Its first product, Iron Sucrose, is being marketed in India. It offers the products for domestic as well as international market. Its products include Iron Sucrose Injection USP, Ondansetron Injection USP, Promethazine Injection BP, Tramadol HCI Injection, Metoclopramide Injection BP, Levetiracetam Injection and Amikacin Injection. The Company registers products in various markets around the world.
Directors
- Last Annual
- December 31st, 2007
- Last Interim
- June 30th, 2008
- Incorporated
- June 26th, 2001
- Public Since
- May 12th, 2006
- No. of Shareholders
- 197
- No. of Employees
- 217
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 23,614,085
- Address
- 509 Maoxiang Street, CHANGCHUN, 130012
- Web
- http://www.globalpharmatech.com/
- Phone
- +86 43185541826
- Auditors
- Moore Stephens
Similar to GBLP
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 20:52 UTC, shares in Global Pharmatech are trading at $0.35. This share price information is delayed by 15 minutes.
Shares in Global Pharmatech last closed at $0.35 and the price had moved by +191.67% over the past 365 days. In terms of relative price strength the Global Pharmatech share price has outperformed the S&P500 Index by +144.78% over the past year.
There is no consensus recommendation for this security.
Global Pharmatech does not currently pay a dividend.
Global Pharmatech does not currently pay a dividend.
Global Pharmatech does not currently pay a dividend.
To buy shares in Global Pharmatech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.35, shares in Global Pharmatech had a market capitalisation of $8.26m.
Here are the trading details for Global Pharmatech:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: GBLP
Based on an overall assessment of its quality, value and momentum Global Pharmatech is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Global Pharmatech. Over the past six months, its share price has outperformed the S&P500 Index by +58.47%.
As of the last closing price of $0.35, shares in Global Pharmatech were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Global Pharmatech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Global Pharmatech's management team is headed by:
- Lianqin Qu - CHM
- Zongsheng Zhang - CFO
- Zhenyou Zhang - DRC